company background image
AMPH

Amphastar Pharmaceuticals NasdaqGS:AMPH Stock Report

Last Price

US$31.32

Market Cap

US$1.5b

7D

-15.3%

1Y

60.4%

Updated

11 Aug, 2022

Data

Company Financials +
AMPH fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance5/6
Financial Health5/6
Dividends0/6

AMPH Stock Overview

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.

Amphastar Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Amphastar Pharmaceuticals
Historical stock prices
Current Share PriceUS$31.32
52 Week HighUS$44.46
52 Week LowUS$17.56
Beta0.67
1 Month Change-12.56%
3 Month Change-11.38%
1 Year Change60.37%
3 Year Change49.86%
5 Year Change112.63%
Change since IPO212.89%

Recent News & Updates

Aug 08

Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond

Amphastar currently has seven drugs under development, two drugs awaiting launch, and a base of over nine FDA-approved products in production. With the recent approval of generic ganirelix and vasopressin, which have a TAM of $850 million, AMPH could nearly double its revenue by YE 2023 with proper execution. Investors with a long time horizon should consider investing in AMPH to benefit from the strong growth prospects presented by the company. Investment Thesis With a diversified portfolio of drugs, Amphastar Pharmaceuticals Inc. (AMPH) is continuously operationalizing its drugs that receive FDA approval and filing new applications. With 3 ANDAs under review by the FDA and seven more under development, AMPH has promising growth prospects in 2H2022 and beyond. Furthermore, with recent approvals, AMPH can anticipate nearly doubling its revenue by the end of 2023 with proper operationalization and execution of the approved drugs. Investors with a broad time horizon and the ability to weather some modest near-term volatility should consider investing in AMPH. Background Amphastar Pharmaceuticals, Inc. is a diversified drug manufacturer that produces various products, including injectibles, biosimilars, complex generic, inhalation, and proprietary products. The main product lines operated by Amphastar are as follows: Enoxaparin: an anticoagulant that prevents blood clots. This drug is abbreviated Enox. Lidocaine Injection and Jelly: Helps reduce patient discomfort during peripheral nerve blocks. Vitamin K1: vitamin K1, obtained from leafy greens and other vegetables, is used to prevent blood clots. Primatene Mist: FDA-approved asthma inhaler is projected to add $100 million to sales by the end of 2024, with an annualized growth rate of 34%. The success is mainly attributable to the physician sampling program and national TV and radio marketing campaigns. Glucagon: Glucagon is a hormone that prevents blood sugar from becoming too low. It is a mature product for Amphastar and is projected to have a positive trajectory in terms of sales and growth. Epinephrine: This drug is used to treat life-threatening allergic reactions. Like glucagon, this product is on a continued growth trajectory for the foreseeable future. This drug is abbreviated "Epi." in the chart below. Naloxone: Similar to suboxone, Naloxone is used to reverse opioid overdose. Naloxone is the second half of suboxone designed to reverse overdoses. Naloxone is also non-addictive because it only works if the person has opioids in their system. The relative contribution of these medications to the overall portfolio of AMPH is shown below. Amphastar Drug Manufacturing Portfolio (Source: Amphastar) Amphastar has the following approved drugs on the horizon in the pipeline for launch and production: Generic Ganirelix: Ganirelix was approved by the FDA on April 4th, 2022. The medication was initially developed by Bristol-Myers Squibb's (BMY) subsidiary Abraxis Bioscience under Abraxane. This drug goes by the generic name albumin-bound paclitaxel. The drug is used to cure female infertility. Amphastar plans to launch the drug production in 2Q2022, which would start to add revenue AMPH production portfolio. Generic Vasopressin: Amphastar received the final approval for its generic vasopressin on July 19th, 2022. Vasopressin controls the body's osmotic balance, blood pressure, sodium homeostasis, and proper kidney functioning. Amphastar anticipates this product's production and subsequent launch in the 3Q2022. In 2Q2022, the price action of Amphastar saw increased volatility due to the rejection of the following ANDA: Generic Teriparatide: On June 14, 2022, Amphastar received a complete response letter, also referred to as CLR, from the FDA, which indicated the drug would not be approved. Teriparatide was the generic version of Eli Lilly's Forteo, used to treat osteoporosis in postmenopausal women. Change in Price for AMPH as a Result of FDA's Rejection of AMP-015 application. (Source: Seeking Alpha) Company Fundamentals The company's quarterly revenue has grown at a rate of 7.7%. The EPS has grown at 37%, as shown below. AMPH Quarterly Revenue Growth Profile (Source: Amphastar) Amphastar Earnings Growth Profile (Source: Amphastar) Although AMPH has been able to accelerate the pace of its ANDA requests, the overall R&D expense has reduced to 14%. This reduction is attributed mainly to the shift from receiving GDUFAs for existing drugs to requesting ANDAs for proprietary products and biosimilar drugs. R&D Spend Optimization by Amphastar (Source: Amphastar) R&D Optimization Transition While Accelerating FDA Requests and New Drug Development (Source: Amphastar) Growth Catalysts The company has 12 Abbreviated New Drug Applications (ANDAs) in progress: Number of ANDAs or Patent Certifications (Paragraph 4 or P-IV) filed with the FDA: 4 Number Rejected: 1 Number Remaining: 3 Number of ANDAs in Development/Clinical Trial Stage: 7 Fully Approved: 2 A complete breakdown of the ANDAs is given below. AMPH R&D Development Breakdown: ANDAs in Progress and ANDAs submitted for FDA Approval (Source: Amphastar)

Shareholder Returns

AMPHUS PharmaceuticalsUS Market
7D-15.3%-0.3%1.2%
1Y60.4%3.2%-11.6%

Return vs Industry: AMPH exceeded the US Pharmaceuticals industry which returned 3.2% over the past year.

Return vs Market: AMPH exceeded the US Market which returned -11.6% over the past year.

Price Volatility

Is AMPH's price volatile compared to industry and market?
AMPH volatility
AMPH Average Weekly Movement10.2%
Pharmaceuticals Industry Average Movement11.7%
Market Average Movement7.9%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.2%

Stable Share Price: AMPH is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: AMPH's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19961,761Jack Zhanghttps://www.amphastar.com

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

Amphastar Pharmaceuticals, Inc. Fundamentals Summary

How do Amphastar Pharmaceuticals's earnings and revenue compare to its market cap?
AMPH fundamental statistics
Market CapUS$1.54b
Earnings (TTM)US$90.91m
Revenue (TTM)US$476.92m

16.9x

P/E Ratio

3.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AMPH income statement (TTM)
RevenueUS$476.92m
Cost of RevenueUS$250.32m
Gross ProfitUS$226.60m
Other ExpensesUS$135.69m
EarningsUS$90.91m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)1.85
Gross Margin47.51%
Net Profit Margin19.06%
Debt/Equity Ratio15.2%

How did AMPH perform over the long term?

See historical performance and comparison